estazolam
Trade name: prosom
Approved
Dec 26, 1990
Estazolam, a triazolobenzodiazepine derivative, is an oral hypnotic agent with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Used for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Marketed under the brand names ProSom, Eurodin. — NCATS
Clinical trial activity
4 trials · 4 clinical orgs · 6 marketing orgs
Earliest trial started Jun 1, 2006 (NCT00347295)
Timeline
1990s
- Dec 26, 1990
Abbott — Earliest FDA Approval
- Dec 26, 1990
Abbott — NDA Organization
- Jul 3, 1997
Par Pharmaceuticals — Marketing Organization
- Jul 3, 1997
Novitium Pharma — Marketing Organization
- Jul 10, 1997
Mayne Pharma — Marketing Organization
- Jul 10, 1997
Dr. Reddy's Laboratories — Marketing Organization
- Aug 19, 1997
Watson Pharmaceuticals — Marketing Organization
2000s
- Jan 1, 2006
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- GABA-A receptor; anion channelPOSITIVE ALLOSTERIC MODULATOR
GABA-A receptor; anion channel positive allosteric modulator
Benzodiazepine site
- Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1) ↗
- Gamma-aminobutyric acid receptor subunit beta-2 (GABRB2) ↗
- Gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2) ↗
- Gamma-aminobutyric acid receptor subunit beta-3 (GABRB3) ↗
- Gamma-aminobutyric acid receptor subunit alpha-4 (GABRA4) ↗
- Gamma-aminobutyric acid receptor subunit gamma-3 (GABRG3) ↗
- Gamma-aminobutyric acid receptor subunit theta (GABRQ) ↗
- Gamma-aminobutyric acid receptor subunit alpha-3 (GABRA3) ↗
- Gamma-aminobutyric acid receptor subunit pi (GABRP) ↗
- Gamma-aminobutyric acid receptor subunit delta (GABRD) ↗
- Gamma-aminobutyric acid receptor subunit gamma-1 (GABRG1) ↗
- Gamma-aminobutyric acid receptor subunit beta-1 (GABRB1) ↗
- Gamma-aminobutyric acid receptor subunit epsilon (GABRE) ↗
- Gamma-aminobutyric acid receptor subunit alpha-2 (GABRA2) ↗
- Gamma-aminobutyric acid receptor subunit alpha-5 (GABRA5) ↗
- Gamma-aminobutyric acid receptor subunit alpha-6 (GABRA6) ↗
- GABA receptor alpha-1 subunit
- GABA receptor beta-2 subunit
- GABA receptor alpha-4 subunit
- GABA receptor delta subunit
- GABA receptor alpha-5 subunit
- GABA receptor alpha-6 subunit
- GABA receptor beta-3 subunit
- GABA receptor alpha-3 subunit
- GABA receptor alpha-2 subunit
- GABA-A receptor; GABA-A site (alpha1/beta2 interface)
- GABA-A receptor; alpha-3/beta-3/gamma-2
- GABA-A receptor; alpha-1/beta-3/gamma-2
- GABA-A receptor; alpha-5/beta-3/gamma-2
- GABA-A receptor; alpha-2/beta-3/gamma-2
- GABA-A receptor; alpha-1/beta-2/gamma-2
- GABA-A receptor; alpha-6/beta-3/gamma-2
- GABA-A receptor; benzodiazepine site
- GABA-A receptor; agonist GABA site
- GABA A receptor alpha-2/beta-2/gamma-2
- GABA A receptor alpha-3/beta-2/gamma-2
- GABA A receptor alpha-6/beta-2/gamma-2
- GABA A receptor alpha-1/beta-1/gamma-2
- GABA A receptor alpha-4/beta-3/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta
- Gamma-aminobutyric acid receptor subunit alpha-1/ beta-1
- Gamma-aminobutyric acid receptor subunit alpha-2/beta-2
- Gamma-aminobutyric acid receptor subunit alpha-3/ beta-2
- Gamma-aminobutyric acid receptor subunit alpha-3/ beta-3/gamma-3
- Gamma-aminobutyric acid receptor subunit alpha-3/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-3/beta-3/theta
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-2
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-3/gamma-3
- Gamma-aminobutyric acid receptor subunit alpha-6/beta-3
- GABA-A receptor alpha-1/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-1/beta-2/delta
- Gamma-aminobutyric acid receptor subunit alpha-4/beta-2/delta
- Gamma-aminobutyric acid receptor subunit beta-1/beta-2
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-2/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-1/alpha-2/beta-2/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-1/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-4/beta-2/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-4/beta-1/delta
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-2/gamma-2
- GABA receptor beta-1 subunit
- Gamma-aminobutyric acid receptor subunit alpha-2/beta-1/gamma-2
Approval history
- approvedDec 26, 1990
Chemistry & pharmacology
SMILES
ClC1=CC=C2N3C=NN=C3CN=C(C4=CC=CC=C4)C2=C1- Mol. weight
- 294.738 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaEstazolam ↗
- NCATS36S3EQV54C ↗
- ChEMBLCHEMBL285674 ↗
Also known as
- 8-chloro-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine
- 8-chloro-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine
- abbott-47631
- abbott-47631
- estazolam
- estazolam
- estazolam
- estazolam
- estazolam
- estazolam
- estazolam
- estazolam
- estazolam
- estazolam
- estazolamum
- estazolamum
- eurodin
- eurodin
- prosom
- prosom
- prosom
- tasedan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05452577 | N/A | Jan 22, 2021 | Nanjing Medical University |
| NCT03997058 | Phase 4 | Jun 1, 2019 | Guangzhou University |
| NCT00956319 | Phase 4 | May 1, 2009 | Astellas |
| NCT00347295 | Phase 3 | Jun 1, 2006 | Boehringer Ingelheim |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 1 | 1 | 1 | 2009 |
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 2006 |
| Guangzhou University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
Marketing (6)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Abbott | For profit | NDA | Dec 26, 1990 |
| Dr. Reddy's Laboratories | For profit | MKTG | Jul 10, 1997 |
| Mayne Pharma | For profit | MKTG | Jul 10, 1997 |
| Novitium Pharma | For profit | MKTG | Jul 3, 1997 |
| Par Pharmaceuticals | For profit | MKTG | Jul 3, 1997 |
| Watson Pharmaceuticals | For profit | MKTG | Aug 19, 1997 |